D360

D360™ is the industry-leading Scientific Informatics Platform developed by Certara, purpose-built for small molecule and sequence-based modalities research. Designed to empower discovery scientists, D360 provides seamless access to enterprise data — spanning compound informatics, bioactivity parameters, and operational data such as inventory — alongside integrated tools for visualization, analysis, and collaboration. Trusted by the top 10 pharmaceutical companies globally and relied upon by more than 6,000 research scientists worldwide, D360 is the analysis and visualization system of choice for discovery teams at both large pharma organizations and innovative biotechs.

By accelerating the Design-Make-Test-Analyze (DMTA) cycle, D360 enables scientists to make the best possible scientific decisions with greater operational efficiency. Its versatility across multiple modalities — including small molecules, peptides, oligos, antibodies, and antibody-drug conjugates (ADCs) — combined with a low total cost of ownership, makes it a comprehensive solution for data-driven drug discovery research.

Core Capabilities and Features

• Self-service data access through intuitive drag-and-drop interfaces, eliminating reliance on research IT teams for routine data queries.
• Shareable queries that can be distributed as one-click dashboard widgets or data views to other research team members.
• Automatic discovery of new assays as they become available, keeping scientists up to date without manual configuration.
• Advanced visualization tools including scatter plots, histograms, and clustering to explore complex datasets with ease.
• Support for multiple research modalities — small molecules, peptides, oligos, antibodies, ADCs, and more — combining general data analytics with structure- and sequence-based analysis.
• Custom dashboard creation and automated data workflows to streamline repetitive analytical tasks.
• Seamless integration with diverse enterprise data sources, enabling a unified view of research and operational data.

Benefits for Scientists and Research IT Teams

• Scientists gain direct, self-service access to research data without depending on IT support, freeing up both groups to focus on higher-value work.
• Consistent data handling and analysis across all supported modalities ensures reproducibility and comparability of results.
• Faster, more informed go/no-go decisions are supported by real-time access to compound and bioactivity data.
• Significant time savings on data analysis — as noted by users, D360 can save hundreds of hours annually on data analysis tasks.
• Scientists spend more time on science and less time on data wrangling, directly contributing to accelerated discovery timelines.

Workflow: Accelerating the Design-Make-Test-Analyze Cycle

1. Query research data efficiently across multiple data sources using drag-and-drop search interfaces.
2. Automatically surface new assay data as it is generated, without manual intervention.
3. Create and share custom visualizations and dashboards with research team members for collaborative analysis.
4. Apply advanced analytics — including scatter plots, histograms, and clustering — to interpret complex datasets.
5. Leverage structure- and sequence-based analysis tools alongside general data analytics to support multi-modality research.
6. Use dynamic data subsets (introduced in D360 v25.5) to divide datasets into compound series and perform separate analyses of each automatically.
7. Make effective go/no-go decisions faster, informed by comprehensive and up-to-date scientific data.

Integrations and Related Products

• D360 integrates with Chemaxon, a complete cheminformatics workbench for molecule design, property calculation, search, and data management.
• Combined use with Design Hub enhances the drug discovery process through an integrated design and analysis workflow.
• An integrated platform variant is available for smaller pharmaceutical teams requiring seamless data access, integration, and analysis.
• Compatible with ToxStudio® for interpreting screening assay data to predict clinical off-target risk and stratify safety early in the DMTA cycle.

D360 is backed by Certara's ISO 27001 certification for its Information Security Management System (ISMS), ensuring robust security controls, rigorous risk assessments, and full compliance with global data protection standards. This provides discovery teams with confidence that sensitive research data is handled securely throughout the analysis process.